OS Therapies Incorporated (OSTX)

NYSEAMERICAN: OSTX · Real-Time Price · USD
3.520
-0.010 (-0.28%)
At close: Sep 18, 2024, 4:00 PM
3.510
-0.010 (-0.28%)
After-hours: Sep 18, 2024, 7:55 PM EDT
-0.28%
Market Cap 73.51M
Revenue (ttm) n/a
Net Income (ttm) -6.55M
Shares Out 20.88M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 105,754
Open 3.530
Previous Close 3.530
Day's Range 3.450 - 3.765
52-Week Range 2.510 - 4.900
Beta n/a
Analysts Strong Buy
Price Target 21.00 (+496.59%)
Earnings Date Aug 15, 2024

About OSTX

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Mary... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2024
Employees 4
Stock Exchange NYSEAMERICAN
Ticker Symbol OSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for OSTX stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target
$21.0
(496.59% upside)
Analyst Consensus: Strong Buy

News

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today annou...

5 days ago - Business Wire

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian ca...

7 days ago - Accesswire

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its par...

13 days ago - Business Wire

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today anno...

20 days ago - Business Wire

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it...

27 days ago - Business Wire

OS Therapies Clarifies CUSIP of Common Stock

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a clarif...

27 days ago - Business Wire

OS Therapies Reports Second Quarter 2024 Financial Results

Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials Conversion of all repor...

4 weeks ago - Accesswire

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stoc...

Other symbols: CANF
5 weeks ago - Accesswire

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

ROCKVILLE, MD / ACCESSWIRE / August 6, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical-stage biopha...

6 weeks ago - Accesswire

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

Other symbols: ACTUGFL
6 weeks ago - Seeking Alpha

OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board

ROCKVILLE, Md. & NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical compa...

6 weeks ago - Business Wire

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”

ROCKVILLE, Md. & NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical stage b...

7 weeks ago - Business Wire

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic can...

2 months ago - Business Wire

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic can...

3 months ago - Business Wire

OS Therapies IPO Registration Document (S-1)

OS Therapies has filed to go public with an IPO on the NYSE American.

1 year ago - SEC